Anavex Life Sciences has announced promising results from its recent Phase
2b/3 clinical trial for Anavex 2-73, an investigational oral therapy aimed at
treating early-stage Alzheimer’s disease. The trial results indicate that
Anavex 2-73 significantly slows cognitive and functional decline among
individuals with mild cognitive impairments or mild dementia due to Alzheimer’s. 

The comprehensivestudy involved 509 participants aged 60 to 85, who were randomly assigned to
receive either one of two doses of Anavex 2-73 or a placebo. Conducted over 48
weeks, the trial assessed the drug’s efficacy using the Alzheimer Disease
Assessment Scale-Cognition (ADAS-Cog) and the Alzheimer’s Disease Cooperative
Study-Activities of Daily Living Scale (ADCS-ADL). 

Participants treated with Anavex 2-73 by Anavex Life Sciences, demonstrated an 84% higher likelihood of experiencing
meaningful cognitive improvement, compared to those receiving a placebo.
Furthermore, those on the treatment exhibited a 45% slower rate of cognitive
decline, supporting its potential as a potent therapeutic option. The drug also
showed a 27% slower decline in cognitive function when measured by the Clinical
Dementia Rating Scale Sum of Boxes (CDR-SB). 

In addition to cognitive benefits, Anavex 2-73 was associated with a significant reduction in
brain volume loss, indicative of slowed neurodegeneration. Blood tests also
revealed a favorable increase in the ratio of amyloid-beta proteins, which are
typically linked to the progression of Alzheimer’s. 

With its strong safety profile, Anavex 2-73 was generally well tolerated, with dizziness being
the most frequent side effect. Participants who completed the trial were
invited to join an open-label extension study, which aims to provide further
insights into the drug’s long-term efficacy and safety. 

Anavex Life Sciences is now preparing to discuss regulatory approval of Anavex 2-73 with
authorities in the U.S., Europe, and the Asia-Pacific region. Anavex marks a significant step forward in the fight against Alzheimer’s,
offering hope to millions affected by this debilitating disease. 

Visit this page on LinkedIn, for related information. 

Learn more about Anavex on https://www.sotcanalytics.com/update-compendium-2024#h.874e6qgoo0o6